Fig. 3From: Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrationsDifferential response rate to PLD chemotherapy according to BRCA1/2 status of sequenced tumour material. * indicates p < 0.05Back to article page